Prosecution Insights
Last updated: November 04, 2026
Application No. 18/766,351

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE

Non-Final OA §112
Filed
Jul 08, 2024
Priority
May 03, 2021 — provisional 63/183,366 +5 more
Examiner
PECKHAM, RICHARD GRANT
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Petra Pharma Corporation
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
96 granted / 141 resolved
+8.1% vs TC avg
Strong +36% interview lift
Without
With
+35.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
61 currently pending
Career history
206
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
28.8%
-11.2% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
30.5%
-9.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 141 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Claims 1, 3-4, 6, 8, 10-12, 14-15, 17, 21-25, 28-29, 42-48, 50-55, 58, 60-61, 63-64, and 66-67 are currently pending. Election/Restriction Applicant’s election without traverse of Group I and Compound 113 PNG media_image1.png 171 238 media_image1.png Greyscale in the reply filed on 7/30/2026 is acknowledged. The compound was searched and found to be free of the art. Subsequently, the Formula of Claim 1 was searched in its entirety and similarly found to be free of the art. Claim 1 of Group I is directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), Group II and all claims belonging thereto, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104. Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, the restriction requirement as set forth in the Office action mailed on 6/04/2026 is hereby withdrawn. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Claim Objections Claims 54-55 and 63-64 are objected to because “a compound” should instead read “the compound” in reference to the compound of Claim 1. Appropriate correction is required. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 64 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for the treatment of cancer associated with PI3K, does not reasonably provide enablement for treatment of cancers not associated with PI3K. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with the claim. In In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have need described. They are: 1. the nature of the invention, 2. the state of the prior art, 3. the predictability or lack thereof in the art, 4. the amount of direction or guidance present, 5. the presence or absence of working examples, 6. the breadth of the claims, 7. the quantity of experimentation needed, and 8. the level of the skill in the art. The nature of the invention (1) and breadth of the claims (6) The nature of the invention and breadth of Claim 64 is the treatment of a cancer comprising administering the compounds of Claim 1 to a patient in need thereof, including PI3K and non-PI3K-associated cancers. Para 61 of the specification states “The term ‘treating’ with regard to a subject, includes restraining, slowing, stopping, or reversing the progression or severity of an existing symptom or disorder”. The state of the prior art (2) and the predictability or lack thereof in the art (3) Zhang (Chem. Sci., 2020, 11, 5855-5865) teaches clearly that “The PI3K pathway is among the most frequently activated in human cancers, impacting almost 50% of the malignancies” (Page 5855). However, this implies that over half of cancers are not associated with activation of this pathway—let alone associated with elevated mutant or WT PI3K levels. Therefore, it is unclear how one might expect to generally treat cancer, which includes non-PI3K associated cancer, with the compounds of the invention in view of the limited varieties of PI3K-modulated cancers. The amount of direction or guidance present (4) and the presence or absence of working examples (5) Tables A (Beginning Page 274) and B (Beginning Page 281) detail the efficacy of the compounds against PI3K activity and the inhibition thereof in WT and mutant variants. However, no nexus between PI3K inhibitory activity and the treatment of non-PI3K-associated cancers is established. The quantity of experimentation needed (7) The quantity of experimentation needed is difficult, novel, and undue experimentation; the ability of the compounds of Claim 1 to treat cancer, including non-PI3K associated cancer, is extremely difficult to determine across all embodiments of the claimed formula and cancer variants and not enabled by the experiments disclosed in the specification of the application. Zhang teaches that less than half of cancers are associated with the general PI3K pathway. It would be undue to establish these associations with respect to each cancer across the large genus of PI3K inhibitors taught in Claim 1 which vary greatly in terms of structure. The level of the skill in the art (8) The level of skill in the art is high; however, even one of the highest skill in the pharmaceutical art would be tasked with the undue experimentation of establishing a nexus between the large amount of claimed compounds and their ability to treat the scope of diseases claimed. Thus, the specification fails to provide sufficient support for the broad use of the claim 1 compounds of the instant claims for the treatment of cancer generally. Allowable Subject Matter The closest prior art is found in Jackson (WO2004016607, cited in 7/08/2026 IDS). Jackson teaches the following compound: 6-methyl-8-(2-carboxy) phenylaminomethyl-2-(4-pyridinyl)-4H-benzopyran-l-one (KN-323), PNG media_image2.png 113 168 media_image2.png Greyscale , on Page 37. Although also taught as a PI3K inhibitor according to Formula (III) of Page 21, PNG media_image3.png 244 442 media_image3.png Greyscale , differs from the examined genus in that the instant R2 position is taught exclusively to be a 5-membered heteroaryl as opposed to the 6-membered heteroaryl of the prior art. Formula (III) does not account for such ring variation and precludes core ring alteration while allowing divergent substitution at various other R positions. Lastly, Formula (I) shown on Page 21 requires a heterocycloalkyl in the same position, which is more dissimilar from the instant genus. Therefore, one of skill in the art, lacking any motivation from Jackson in the form of a teaching or suggestion of variability would not find it obvious to modify the core ring of Jackson to form a smaller heterocycle. Similar double patenting considerations were made over at least copending applications No. 19126418 and 19126421 and US Patent No. 11873295 wherein all three are limited to carbocyclic aryl groups at the instant R2 position. Conclusion Claims 1, 3-4, 6, 8, 10-12, 14-15, 17, 21-25, 28-29, 42-48, 50-53, 58, 60-61, and 66-67 are allowable. Claim is 64 are rejected. Claims 54-55 and 63-64 are objected to. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Peckham whose telephone number is (703)756-4621. The examiner can normally be reached 8:30am - 4:30pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD GRANT PECKHAM/Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Jul 08, 2024
Application Filed
Sep 11, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773403
SCOPOLAMINE COMPOSITIONS AND TRANSDERMAL PATCHES MADE THERRFROM
5y 1m to grant Granted Oct 27, 2026
Patent 12773401
Pharmaceutical compositions of Ovatodiolide and the use thereof
4y 10m to grant Granted Oct 27, 2026
Patent 12774277
AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS
3y 5m to grant Granted Oct 27, 2026
Patent 12748101
COMPOSITION AND METHOD FOR INHIBITING BORC COMPLEX TO TREAT CANCERS WITH NF1 DEFICIENCY AND DYSREGULATED RAS SIGNALING
4y 6m to grant Granted Sep 29, 2026
Patent 12735425
6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT
3y 3m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+35.8%)
3y 3m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 141 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month